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Advantages of Plasmid DNA Vaccines
? Proven platform technology that 
induces humoral and cellular 
responses in animals
? 3 animal health vaccines approved
? Potential to prime strong memory 
responses
? Evidence of safety and immunogenicity 
in humans with and without adjuvants
? No infectious components
? Fermentation-based manufacturing 














































• Dose sparing with DNA and 
protein-based vaccines




Antigen Species Immunogenicity Reference
Influenza NP Mice
Rabbits
↑ NP Ab titers 20X
↑ NP Ab titers 50X
Hartikka, Vaccine 19:1911; 2001
NP and various other antigens Mice ↑ Ab titers 3-10X Reyes, Vaccine 19: 3778; 2001
Tuberculosis Ag85 Mice ↑ Ag85 Ab titers 3-10X D’Souza, Inf Imm 70: 3681; 2002
Influenza NP or hGH Rats ↑ NP Ab titers and CTLs Sankar, Oral Dis 8: 275; 2002
JEV prM/E Mice ↑ Neut Ab titers 8X Nukuzuma, Vir Imm 16: 183; 2003
HIV-2 Env Mice ↑ Serum and mucosal Ab Locher, DNA Cell Biol 23: 107; 2004
HIV-2 Env tat nef gag/pro Baboons Partial protection from HIV-2 Locher, Vaccine 22: 2261; 2004
Plasmodium yoelli CSP Mice ↑ Ab titers, ELISPOT responses, 
protection
Sedegah, Vaccine 24: 1921; 2006
Rabies G protein Mice
Rabbits
Protective neutralizing titers sustained 
120 days
Margalith, Gen Vacc Ther 4: 1; 2006
Tuberculosis Ag85 Mice ↑ Cytokines but not survival against 
MTB





↑ Neut Ab and protection
↑ Ab titers at 5 months vs rPA in 
Alhydrogel
Hermanson, PNAS 101: 13601; 2004
Hahn, Vaccine 24: 4795; 2006
Influenza HA, NP, M2 Mice
Mice/Ferrets
↑ # of IFNγ T cells vs PBS-formulation
Protection against H5N1 challenge
Jimenez, Human Vaccines; 2007
Lalor et al., JID; 2008
Vaxfectin®-enhanced Antibody Responses 
IL-6 Dependency
Reyes et al., Vaccine 2001
• ↑ serum IL-6 at 4 hrs (p < 0.05)
• ↓ serum anti-NP antibody  
titers in IL-6-/- mice (p = 0.02)
IM injections in C57BL/6 mice (5 μg NP pDNA in each rectus femoris) 
at 0 and 3 weeks; IgG titers (mean + SEM) at 6 weeks
N = 5
N = 10
Vaxfectin® Mechanism of Action
Induction of Immunostimulatory Gene Expression
Analysis of transcript levels (Affymetrix DNA Chip: 39,000 transcript represented) in mouse muscles (N =3) 
at 24 and 48h after IM injection of cationic lipid (Vaxfectin® or DMRIE:DOPE)-formulated VR6365 pDNA
(Fold-increase over injected VR6365/PBS muscles with p < 0.05)
Pandemic Influenza DNA Vaccine Strategy
Goal: Develop a vaccine that is efficacious for current 
perceived threats that will also be beneficial in the 
event of a mismatched pandemic virus
? Select HA component for current H5 threat
? Select highly conserved proteins to enable cross protection
? Create consensus sequences (>85% identical)
? Test to determine lead constructs and formulation
? Evaluate preclinical efficacy
? Evaluate preclinical safety
? Evaluate in the clinic
Pandemic Influenza DNA Vaccine
Product profile
? H5 HA (A/Vietnam/1203/04)
? Conserved NP + M2 for cross-protection
? Vaxfectin® adjuvant
? 1 or 2 IM (possibly ID) injections
? 1 mg dose or less
? Needle or Biojector® 2000
Comprehensive immune responses
? Antibodies against HA and M2
? T cells against all encoded antigens















Mouse-adapted A/HK/8/68 (H3N2) challenge
or











Week 3 Week 6-8
Vaccination Regimen Challenge Regimen
? Vaxfectin® and DMRIE:DOPE provide 
significant survival benefit over 



























Cationic Lipids vs. Poloxamer vs. PBS
(50%)
M2 ELISPOTS


























































Influenza Challenge Model (H3N2)
? Vaxfectin® provides significant survival benefit over 
DMRIE:DOPE at low doses






















5 μg NP+M2/Vax (84%)
2 μg NP+M2/DM:DP (20%)
H1 HA (0%)
5 μg NP+M2/DM:DP (68%)
Days After Challenge
2 μg NP+M2/Vax (72%) p<0.001
Jimenez, Human Vaccines 2007
? Vaxfectin®-formulated NP+M2 provides cross strain 














































60 µg NP+M2 (100%); or H1 HA
2 µg NP+M2 (33 )
H3 HA; or naïve (0%)
20 µg NP+M2 (80%)
Cross-strain Protection
Influenza Challenge Model (H1N1) 
Survival: Vaxfectin®-formulated NP + M2 
? H3 HA formulated with Vaxfectin® protects against H3N2 







0 3 6 9 12 15 18 21
0.08 µg H3/Vaxfectin® (60%)
50 µg H3/PBS (100%)
2 µg H3/PBS (100%)
2 µg H3/Vaxfectin® (100%)
0.4 µg H3/Vaxfectin® (100%)
0.4 µg H3/PBS (0%)












Dose-sparing Effect of Vaxfectin®























Inactivated HA vaccine 
H5
H5 + NPav + M2av 




p<0.001 by log-rank test
p<0.001 by log-rank test
BALB/c mice (n = 16 / group) vaccinated at Days 0, 21 with 33 μg each Vaxfectin®-formulated pDNA or 
inactivated H5N1 vaccine (15 μg HA);  A/Vietnam/1203/04 challenge (100 x LD50) at Day 42 
Collaboration with Dr. Richard Webby at St Jude Children’s Research Hospital 
DNA-based Pandemic Influenza Vaccine
























































)H5 + M2av + NPav
pDNA backbone
P value = 0.0009 
by log rank test
DNA-based Pandemic Influenza Vaccine
Ferret H5N1 Challenge - Survival, Weight Loss
Collaboration with Dr. Richard Webby
St. Jude Children’s Research Hospital 
Fitch ferrets (n = 6 / group) serologically H5N1 flu-free vaccinated at Days 0 and 21 with 1.0 mg total 
Vaxfectin®-formulated pDNA; A/Vietnam/1203/04 challenge (100 x LD50) at Day 42
Lalor et al., JID 2008
Fitch ferrets (n = 6 / group) serologically H5N1 flu-free vaccinated at Days 0 and 21 or Day 21 only (1X) 
with 0.3 mg each Vaxfectin®-formulated pDNA;  A/Vietnam/1203/04 challenge (100 x LD50) at Day 42 
Collaboration with Dr. Richard Webby at St Jude Children’s Research Hospital 
p<0.001 by log-rank test
























H5 + NPhu + M2hu 
H5 + NPhu + M2hu (1X)
NPhu + M2hu 
pDNA backbone
DNA-based Pandemic Influenza Vaccine 
Ferret H5N1 Challenge Study - Survival
HI titers in vaccinated ferrets prior to vaccination (Day 0), on Days 14 and 35, and 3 weeks after infection with 
A/Vietnam/1203/04 (Day 63); virus titers in the upper respiratory tract of vaccinated and control ferrets measured 
from nasal washes collected on Days 3, 5, and 7 after infection
DNA-based Pandemic Influenza Vaccine
Ferret H5N1 Challenge Study





































































Day 0 Day 14






Vaxfectin®-formulated Influenza Vaccine 
GLP Tissue Distribution in Rabbits
Single bilateral i.m. injection of 0.5 mg DNA/0.5 mL/muscle [~28X human dose (mg/kg)]; 5 rabbits/sex/timepoint;      
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Vaxfectin®-formulated Influenza Vaccine 
Phase 1 Clinical Trials
? Double-blind placebo controlled study
? Dose escalation 0.1 to 1 mg total DNA
? Vaxfectin®-formulated H5 + NP + M2 or H5 alone
? Vaccinations IM on Days 0 and 21
? Needle or Biojector® 2000
? 103 normal healthy adults (18-45 yrs)
? 3 clinical sites: SNBL (Maryland), Stony Brook (New York), 
Accelovance (San Diego)
? Safety, tolerability, immunogenicity
? Antibodies measured by HI and neutralizing assays 
? T-cell responses measured by ELISPOT assays
Pandemic Influenza DNA Vaccine 
Summary
? Mouse studies at Vical
? In the absence of HA, NP + M2 provides the best cross strain 
protection in mice
? Vaxfectin® adjuvant provides dose-sparing advantage
? Mouse and ferret H5N1 studies at SJCRH
? 100% protection in mice and ferrets with H5 + NP + M2 
? 1 dose vaccine protects ferrets against Vietnam H5N1 strain
? High-level protection in mice with NP + M2 vaccine
? GLP safety studies
? Rabbit repeat dose study demonstrates safety
? Clearance over time with no evidence of integration
? Two ongoing clinical trials
Vaxfectin®-formulated DNA Vaccine
Protection of Macaques against Measles
? Juvenile rhesus macaques (2 yrs)
? H + F DNA on Days 0, 28
? 0.5 mg ID (n= 5)
? 1 mg IM (n = 5)
? Challenge at Week 55 with 104 TCID50
of Bilthoven strain intratracheally
? No clinical signs of measles and no 
viremia in vaccinated animals
? Rash and viremia in controls
? Infant macaques (6-8 wks) - 2nd study
? Challenge at 1 year
? No clinical signs or viremia 
Collaboration with Dr. D. Griffin, Johns Hopkins
Pan et al., Clinical and Vaccine Immunology (2008)
Needle-free Injection of Vaxfectin®-
formulated DNA vs Electroporation
? IM or ID delivery of Vaxfectin®-formulated pDNA (hCMV gB) vaccine delivered with 
needle-free device resulted in anti-gB titers similar to those obtained with EP-assisted 
delivery (historical study)












































Vaxfectin® as an Adjuvant for Protein-
based Vaccines
Fluzone®
• Split inactivated trivalent inactivated flu vaccine (TIV; from 
sanofi pasteur) 
• 2006-07 formulation contains 15 μg of each HA (A/New 
Caledonia/20/99 [H1N1], A/Wisconsin/67/2005 [H3N2], and 
B/Malaysia/2506/2004) per 0.5 mL 
+ Vaxfectin®
Vaxfectin® as Dose-sparing Adjuvant
Protein-based Influenza Vaccine
BALB/c mice (n = 10 / group) injected IM with Vaxfectin®-formulated protein on Days 0 and 21
? Vaxfectin® at any dose of TIV (Fluzone®) significantly (p <0.001) increased 
HI titers in mice compared to TIV alone
? Dose-sparing for protein vaccines (>10x)
















































0.1 µg TIV 
260
0.45.310.0


















Vaxfectin® as a Th1 Adjuvant
Anti-TIV IgG Isotypes
Conclusions: 
?With 0.1 µg total TIV 
dose, IgG1 is the 
dominant isotype
? Vaxfectin® (900 µg) 
increased IgG2/3 titers 
more than IgG1 titers, 
resulting in a more 
balanced isotype 
distribution









? Vical’s Product Discovery-
Development Teams and 
Departments
? SJCRH and Johns Hopkins 
Researchers
? Clinical investigators
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